Operational Costs Compared: SG&A Analysis of Viatris Inc. and MiMedx Group, Inc.

SG&A Expenses: Viatris vs. MiMedx Over a Decade

__timestampMiMedx Group, Inc.Viatris Inc.
Wednesday, January 1, 2014904800001499100000
Thursday, January 1, 20151333840001923500000
Friday, January 1, 20161799970002351400000
Sunday, January 1, 20172201190002564000000
Monday, January 1, 20182585280002397300000
Tuesday, January 1, 20191982050002503400000
Wednesday, January 1, 20201810220003344600000
Friday, January 1, 20211983590004529200000
Saturday, January 1, 20222087890004179100000
Sunday, January 1, 20232111240004650100000
Loading chart...

Igniting the spark of knowledge

Analyzing SG&A Expenses: Viatris Inc. vs. MiMedx Group, Inc.

In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. A key indicator of this efficiency is the Selling, General, and Administrative (SG&A) expenses. Over the past decade, Viatris Inc. and MiMedx Group, Inc. have showcased contrasting trends in their SG&A expenditures.

A Decade of Financial Insights

From 2014 to 2023, Viatris Inc. consistently reported higher SG&A expenses, peaking at approximately $4.65 billion in 2023, a staggering 210% increase from 2014. In contrast, MiMedx Group, Inc. maintained a more modest growth, with expenses rising by about 133% over the same period, reaching around $211 million in 2023.

These figures highlight Viatris's expansive operational scale compared to MiMedx. As the industry continues to evolve, understanding these financial dynamics is crucial for stakeholders aiming to navigate the competitive pharmaceutical market.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025